Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

NCT04423718 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04423718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04423718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
August 11, 2020
Completion date
August 7, 2024
Enrollment
1,011 (actual)
Sites
235

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration